3 Biotech Stocks Falling Like a Knife: Puma Biotechnology, MacroGenics, and Aratana Therapeutics
George Budwell, The Motley Fool - Motley Fool - Mon Apr 14, 1:30PM CDT
Biotech stocks have been in near free-fall the past month, with the iShares Nasdaq Biotechnology Index dropping a noteworthy 15.4%. While this could be part of a general market correction, such a dramatic decline may indicate deeper issues with...
Aratana Therapeutics Adds David Brinkley to Board of Directors
PR Newswire - Thu Mar 27, 6:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced the appointment of former Theravance executive David L. Brinkley to its Board of Directors. Mr. Brinkley's broad expertise spans business development, marketing, and animal health, for both mid- and large size biopharmaceutical companies.
Advaxis Discusses Global Licensing Agreement for Pet Therapeutics on Conference Call
GlobeNewswire - Thu Mar 20, 11:45AM CDT
Advaxis, Inc. (Nasdaq:ADXS), a biotechnology company developing the next generation of cancer immunotherapies, hosted a joint conference call with Aratana Therapeutics (Nasdaq
Aratana and Advaxis Enter Exclusive Global Licensing Agreement
PR Newswire - Wed Mar 19, 7:01PM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, and Advaxis, Inc. (NASDAQ: ADXS), a biotechnology company developing the next generation of cancer immunotherapies, today announced a global licensing agreement for Advaxis' ADXS-cHER2 for the treatment of osteosarcoma in dogs and three additional cancer immunotherapy products for the treatment of three other types of cancer. Each of the four licensed products is based on Advaxis' platform immunotherapy technology, which Advaxis is developing for the treatment of human cancers on a global basis. Under the agreement, Aratana will have exclusive rights to develop and commercialize the licensed immunotherapies for pet health applications, and will focus initially on developing ADXS-cHER2 for osteosarcoma.
Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
What Falling Estimates & Price Mean for Cempra (CEMP) - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 7:45AM CDT
Cempra has witnessed a significant price decline in the past four weeks. The reason is negative trend in earnings estimate revisions. The stock also has seen some pretty dismal trading lately.
Aratana (PETX) Enters Oversold Territory - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 14, 6:56AM CDT
Aratana (PETX) Enters Oversold Territory
Aratana Therapeutics Reports Fourth Quarter and Full Year 2013 Results
PR Newswire - Thu Mar 13, 6:30AM CDT
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for cats, dogs and other companion animals, today announced its fourth quarter and full year 2013 financial results.
Aratana Therapeutics to Report Fourth Quarter and Full Year 2013 Financial Results
PR Newswire - Tue Mar 11, 7:59PM CDT
Aratana Therapeutics, Inc. (Nasdaq: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, will host a conference call and live audio webcast on Thursday, March 13, 2014, at 8:00 a.m. ET, to discuss its financial results for the quarter ended December 31, 2013.
IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.
Aratana Therapeutics to Present at Two Upcoming Investor Conferences
PR Newswire - Thu Mar 06, 4:12PM CST
Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing or acquisition, development and commercialization of innovative biopharmaceutical products for cats, dogs and other companion animals, today announced that it will present at two upcoming investor events. Aratana will present at the Barclays Global Healthcare Conference, to be held March 11-13, 2014, in Miami, Florida, and also the Jefferies Animal Health Day, to be held March 27, 2014, in New York City.
Portola Pharmaceuticals (PTLA) Jumps: Stock Up 8.3% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 7:51AM CST
Portola Pharmaceuticals, Inc. was a big mover last session, as its shares rose over 8% on the day.
Nektar Therapeutics (NKTR) Jumps: Stock Up 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 04, 8:39AM CST
Nektar Therapeutics was a big mover last session, as its shares rose nearly 11% on the day.
BioCryst Pharmaceuticals (BCRX) Jumps: Stock Rises 10.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 8:39AM CST
BioCryst Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 11% on the day.
Infinity Pharmaceuticals (INFI) Jumps: Stock Adds 15.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Feb 26, 7:51AM CST
Infinity Pharmaceuticals, Inc. was a big mover last session, as its shares rose almost 16% on the day.
RXi Pharmaceuticals (RXII) Jumps: Stock Adds 28.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 25, 7:51AM CST
RXi Pharmaceuticals Corporation was a big mover last session, as its shares rose almost 29% on the day.
Cempra (CEMP) Jumps: Stock Adds 6.1% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 21, 8:39AM CST
Cempra, Inc. was a big mover last session, as its shares rose just over 6% on the day.
Aratana Therapeutics (PETX) Jumps: Stock Moves 7.3% Higher - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 8:46AM CST
Aratana Therapeutics was a big mover last session, with shares rising over 7%.
Will Regeneron (REGN) Disappoint in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 3:30PM CST
Regeneron is set to report its fourth quarter 2013 results on Feb 11 before the opening bell.
5 Biotech Stocks Spiking on Unusual Volume
at The Street - Mon Feb 10, 7:42AM CST
Often when above-average volume moves into an equity, it precedes a large spike in volatility.